Press release – price-sensitive

PRICE-SENSITIVE  |  NON PRICE-SENSITIVE

27/06/2022

APPROVED FINANCING AND AWARDING OF FUNDING FOR THE “SmartLAB” PROJECT WITH A VALUE OF € 1 MILLION

18/05/2022

TURNOVER FOR THE FIRST THREE MONTHS OF 2022 IN STRONG GROWTH AT 1.0 MILLION EUROS, +22.93% COMPARED TO THE SAME PERIOD IN 2021

13/05/2022

ARTERRA LAUNCHES THE BUYBACK PROGRAM OF ORDINARY TREASURY SHARES - WEEKLY INFORMATION REGARDING THE PURCHASE OF TREASURY SHARES

21/04/2022

FILING AND PUBLICATION OF THE LISTS FOR THE APPOINTMENT OF THE MEMBERS OF THE BOARD OF DIRECTORS AND THE BOARD OF STATUTORY AUDITORS

06/04/2022

COMPLETED BY ISAGRO S.P.A. AND MAARTEN CHRISPEELS THE SALE OF 1,551,000 ORDINARY SHARES OF ARTERRA BIOSCIENCE S.P.A., EQUAL TO ABOUT 23.3% OF THE SHARE CAPITAL, AT A PRICE OF EUR 1.83 PER SHARE

05/04/2022

START OF SALE OF A MAXIMUM OF 1,552,655 ORDINARY SHARES ARTERRA BIOSCIENCE S.P.A. BY ISAGRO S.P.A. AND MAARTEN CHRISPEELS THROUGH AN ACCELERATED BOOKBUILDING PROCEDURE RESERVED TO INSTITUTIONAL AND PROFESSIONAL INVESTORS

30/03/2022

THE BOARD OF DIRECTORS APPROVED THE DRAFT FINANCIAL STATEMENTS AS OF DECEMBER 31, 2021

21/12/2021

ARTERRA BIOSCIENCE S.P.A. TRANSFERS THE PARTICIPATION ADL FARMACEUTICI SRL. TO D&B PHARMA SRL.

23/11/2021

ARTERRA BIOSCIENCE S.P.A. RESOLVES THE SUBSCRIPTION OF A SHARE OF THE CAPITAL INCREASE OF ADL FARMACEUTICI S.R.L.

29/10/2021

ARTERRA COMMUNICATES THE TERMINATION OF THE SECOND EXERCISE PERIOD OF THE ARTERRA WARRANTS 2019-2022

01/10/2021

ARTERRA COMMUNICATES THE OPENING OF THE SECOND EXERCISE PERIOD OF THE ARTERRA WARRANTS 2019-2022

28/09/2021

ARTERRA BIOSCIENCE S.P.A. PARTICIPATES IN THE INNCOCELLS PROJECT - AN EU-FUNDED HORIZON 2020 PROJECT THAT DEVELOPS SAFE AND SUSTAINABLE COSMETIC INGREDIENTS DERIVED FROM PLANTS

27/09/2021

THE BOARD OF DIRECTORS APPROVED THE HALF-YEAR REPORT AS OF JUNE 30, 2021

25/06/2021

ARTERRA BIOSCIENCE S.P.A. SUBSCRIBES SHARE OF THE CAPITAL INCREASE OF ADL FARMACEUTICI S.R.L. AND A NEW RESEARCH AND DEVELOPMENT CONTRACT

SIGNING OF A COLLABORATION AGREEMENT WITH MONTECARLOFRUIT

29/04/2021

ORDINARY AND EXTRAORDINARY SHAREHOLDERS 'MEETING OF ARTERRA BIOSCIENCE S.P.A.

07/04/2021

SUPPLY AGREEMENT AND BRAND LICENSE SIGNED BETWEEN ARTERRA BIOSCIENCE S.P.A. AND ADL FARMACEUTICI S.R.L. FOR THE REALIZATION AND MARKETING OF MEDICAL DEVICES

06/04/2021

PUBLICATION OF THE CALL FOR THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING

29/03/2021

THE BOARD OF DIRECTORS APPROVED THE DRAFT FINANCIAL STATEMENTS AS OF DECEMBER 31, 2020

03/11/2020

EXERCISE OF 26,313 WARRANTS DURING THE FIRST YEAR PERIOD - ADJUSTMENT TO THE PRESS RELEASE OF OCTOBER 29, 2020

29/10/2020

ARTERRA COMMUNICATES THE CLOSURE OF THE FIRST EXERCISE PERIOD OF THE ARTERRA WARRANTS 2019-2022

01/10/2020

ARTERRA COMMUNICATES THE OPENING OF THE FIRST EXERCISE PERIOD OF THE ARTERRA WARRANTS 2019-2022

30/09/2020

THE BOARD OF DIRECTORS APPROVED THE HALF-YEAR REPORT AS OF JUNE 30, 2020

04/08/2020

A PATENT RELATING TO THE IDENTIFICATION OF A NATURAL COMPOUND CAPABLE OF INTERFERING WITH COVID-19 INFECTION WITH POSSIBLE APPLICATIONS IN DIFFERENT INDUSTRIAL SECTORS HAS BEEN FILED

03/07/2020

ARTERRA COMMUNICATES THE SUBSCRIPTION OF THE ADDENDUM TO VITALAB’S SHAREHOLDER AGREEMENT WITH THE INTERCOS GROUP

30/06/2020

ARTERRA COMMUNICATES THE EXTENSION OF THE DEADLINE FOR THE APPOINTMENT OF THE CFO TO JUNE 30, 2021

29/06/2020

ARTERRA COMMUNICATES THE FREE ALLOCATION OF SHARES IN FAVOR OF ITS EMPLOYEES

19/06/2020

ARTERRA COMMUNICATES THE FREE ALLOCATION OF SHARES IN FAVOR OF ITS EMPLOYEES

30/04/2020

WEEKLY INFORMATION REGARDING THE PURCHASE OF TREASURY SHARES

29/04/2020

ORDINARY SHAREHOLDERS’ MEETING OF ARTERRA BIOSCIENCE S.P.A.

24/04/2020

WEEKLY INFORMATION REGARDING THE PURCHASE OF TREASURY SHARES

17/04/2020

WEEKLY INFORMATION REGARDING THE PURCHASE OF TREASURY SHARES

31/03/2020

THE BOARD OF DIRECTORS APPROVED THE DRAFT FINANCIAL STATEMENTS AS OF DECEMBER 31, 2019

14/11/2019

THE BOARD OF DIRECTORS OF ARTERRA BIOSCIENCE S.P.A. APPROVES THE QUARTERLY FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2019

28/10/2019

FIRST TRADING DAY OF ARTERRA'S ORDINARY SHARES AND WARRANTS ON THE AIM ITALIA MARKET

24/10/2019

ARTERRA BIOSCIENCE ADMITTED FOR TRADING ON THE AIM ITALIA MARKET

10/10/2019

ARTERRA BIOSCIENCE S.P.A. BOOKBUILDING LAUNCHED PRE-ADMISSION APPLICATION SUBMITTED.

30/03/2022

THE BOARD OF DIRECTORS APPROVED THE DRAFT FINANCIAL STATEMENTS AS OF DECEMBER 31, 2021

06/04/2022

COMPLETATA DA PARTE DI ISAGRO S.P.A. E MAARTEN CHRISPEELS LA CESSIONE DI N. 1.551.000 AZIONI ORDINARIE ARTERRA BIOSCIENCE S.P.A., PARI A CIRCA IL 23,3% DEL CAPITALE SOCIALE, AD UN PREZZO DI EURO 1,83 PER AZIONE

Press release – price-sensitive

PRICE-SENSITIVE  |  NON PRICE-SENSITIVE

27/06/2022

APPROVED FINANCING AND AWARDING OF FUNDING FOR THE “SmartLAB” PROJECT WITH A VALUE OF € 1 MILLION

18/05/2022

TURNOVER FOR THE FIRST THREE MONTHS OF 2022 IN STRONG GROWTH AT 1.0 MILLION EUROS, +22.93% COMPARED TO THE SAME PERIOD IN 2021

13/05/2022

ARTERRA LAUNCHES THE BUYBACK PROGRAM OF ORDINARY TREASURY SHARES - WEEKLY INFORMATION REGARDING THE PURCHASE OF TREASURY SHARES

21/04/2022

FILING AND PUBLICATION OF THE LISTS FOR THE APPOINTMENT OF THE MEMBERS OF THE BOARD OF DIRECTORS AND THE BOARD OF STATUTORY AUDITORS

06/04/2022

COMPLETED BY ISAGRO S.P.A. AND MAARTEN CHRISPEELS THE SALE OF 1,551,000 ORDINARY SHARES OF ARTERRA BIOSCIENCE S.P.A., EQUAL TO ABOUT 23.3% OF THE SHARE CAPITAL, AT A PRICE OF EUR 1.83 PER SHARE

05/04/2022

START OF SALE OF A MAXIMUM OF 1,552,655 ORDINARY SHARES ARTERRA BIOSCIENCE S.P.A. BY ISAGRO S.P.A. AND MAARTEN CHRISPEELS THROUGH AN ACCELERATED BOOKBUILDING PROCEDURE RESERVED TO INSTITUTIONAL AND PROFESSIONAL INVESTORS

30/03/2022

THE BOARD OF DIRECTORS APPROVED THE DRAFT FINANCIAL STATEMENTS AS OF DECEMBER 31, 2021